Sinopharm Subsidiary Sinopharm Accord Reports Q3 Revenue Decline
I'm PortAI, I can summarize articles.
Sinopharm Group Co. Ltd. reported that its subsidiary, China National Accord Medicines Corporation Ltd. (Sinopharm Accord), experienced a revenue decline of 1.89% year-on-year, totaling RMB 18.33 billion for Q3 2025. However, total assets increased by 6.31% to RMB 50.56 billion, and equity attributable to shareholders rose by 4.30% to RMB 18.43 billion compared to the previous year.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments